ORLEX HC
Clinical safety rating
cautionComprehensive clinical and safety monograph for ORLEX HC (ORLEX HC).
Hydrocodone is a full opioid agonist with relative selectivity for mu-opioid receptors, though it can bind to other opioid receptors at higher doses. Its analgesic effects are mediated via modulation of nociceptive pathways in the CNS. Homatropine is an anticholinergic agent that reduces excessive respiratory tract secretions by blocking muscarinic receptors.
| Metabolism | Hydrocodone is metabolized primarily via CYP3A4 and CYP2D6 to hydromorphone (active) and norhydrocodone (inactive). Homatropine is metabolized via hepatic enzymes, exact pathways not well characterized. |
| Excretion | ORLEX HC contains Hydrocodone and Homatropine. Hydrocodone: primarily renal elimination (~85% as metabolites, ~5% unchanged). Homatropine: biliary/fecal (up to 70%) and renal (30%). |
| Half-life | Hydrocodone: terminal half-life 3.8-5.6 hours (mean ~4.5 h) in adults; clinically, steady state in ~1-2 days. Homatropine: ~8-12 hours. |
| Protein binding | Hydrocodone: ~20-30% bound, primarily to albumin. Homatropine: ~15% bound to albumin. |
| Volume of Distribution | Hydrocodone: 3.3-4.7 L/kg (extensive tissue distribution). Homatropine: ~1-2 L/kg. |
| Bioavailability | Hydrocodone: oral bioavailability ~50-70% (first-pass effect). Homatropine: oral bioavailability ~10-20% (poor absorption and first-pass). |
| Onset of Action | Hydrocodone: oral onset 10-30 minutes. Homatropine: oral onset 30-60 minutes. |
| Duration of Action | Hydrocodone: 4-6 hours (analgesic). Homatropine: up to 6 hours (anticholinergic). |
| Molecular Weight | 534.5 |
1 capsule (hydrocortisone 5 mg, phenylephrine 5 mg, chlorpheniramine 4 mg) orally every 4-6 hours as needed, not exceeding 6 capsules per day.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No specific dose adjustment recommended. Use with caution in severe renal impairment (eGFR <30 mL/min/1.73m²) due to risk of phenylephrine accumulation and hypertension. |
| Liver impairment | No specific dose adjustment recommended. Use with caution in severe hepatic impairment (Child-Pugh Class C) due to potential increased exposure to hydrocortisone and chlorpheniramine. |
| Pediatric use | Not recommended for children under 12 years. For ages 12-17: 1 capsule orally every 4-6 hours, max 6 capsules/day. |
| Geriatric use | Initiate at lowest effective dose (e.g., 1 capsule every 6 hours) and monitor for anticholinergic effects (chlorpheniramine) and hypertension (phenylephrine). Avoid in patients with uncontrolled hypertension or narrow-angle glaucoma. |
| 1st trimester | Avoid use; potential teratogenic effects with prolonged use. |
| 2nd trimester | Use only if clearly needed; may cause adrenal suppression in fetus. |
| 3rd trimester | Avoid; risk of neonatal adrenal suppression and premature delivery. |
Clinical note
Comprehensive clinical and safety monograph for ORLEX HC (ORLEX HC).
| Placental transfer | Crosses placenta; degree depends on corticosteroid potency and dose. |
| Breastfeeding | Excreted in breast milk; may suppress infant adrenal function. Use only if benefit outweighs risk. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Cleft lip/palate, neural tube defects; late pregnancy: premature closure of ductus arteriosus, oligohydramnios, fetal renal impairment; third trimester: neonatal adrenal suppression. |
| Fetal Monitoring | Monitor fetal growth and amniotic fluid volume via ultrasound; assess ductus arteriosus flow in third trimester; maternal blood pressure and glucose. |
| Fertility Effects | No proven effect on fertility; chronic use may impair ovulation. |
■ FDA Black Box Warning
Risks of addiction, abuse, misuse; life-threatening respiratory depression; accidental ingestion (especially fatal in children); neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risks from concomitant use with benzodiazepines or other CNS depressants; risk of medication errors due to multiple strengths and formulations.
| Serious Effects |
Hypersensitivity to any componentSystemic fungal infectionsAdministration of live vaccines
| Precautions | Respiratory depression; drug dependence and abuse; head injury/increased intracranial pressure; acute abdominal conditions; concurrent use with CNS depressants; elderly/debilitated patients; severe renal or hepatic impairment; hypothyroidism; Addison's disease; prostatic hyperplasia; urinary retention; pregnancy; lactation. |
| Food/Dietary | No clinically significant food interactions. |
| Clinical Pearls | ORLEX HC (hydrocortisone/neomycin/polymyxin B) is an otic suspension. Use for acute otitis externa when the tympanic membrane is intact. Avoid if perforation is suspected, as neomycin is ototoxic. Shake well before use. Contraindicated in viral or fungal infections. Monitor for sensitization to neomycin. |
| Patient Advice | Instill 4 drops into the affected ear(s) 3-4 times daily. · Keep the ear dropper bottle upright to avoid contamination. · Lie on your side for 5 minutes after instillation to allow medication to coat the ear canal. · Complete the full course even if symptoms improve. · Do not share the medication with others. · Report any signs of allergic reaction (rash, itching, swelling) to your doctor. · Do not use if you have a perforated eardrum or ear tube. |
Loading safety data…